Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DIAGNOSTIC_TEST: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS